Ionis Pharmaceuticals IONS Payments to Acquire Intangible Assets
Payments to Acquire Intangible Assets at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's payments to acquire intangible assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's payments to acquire intangible assets?
- Ionis Pharmaceuticals (IONS) reported payments to acquire intangible assets of $1.49M in Q1 2026.
- How has Ionis Pharmaceuticals's payments to acquire intangible assets changed year-over-year?
- Ionis Pharmaceuticals's payments to acquire intangible assets increased by 128.3% year-over-year, from $651K to $1.49M.
- What is the long-term trend for Ionis Pharmaceuticals's payments to acquire intangible assets?
- Over 3 years (2021 to 2025), Ionis Pharmaceuticals's payments to acquire intangible assets has grown at a -1.7% compound annual growth rate (CAGR), from $5.95M to $5.64M.
- What does payments to acquire intangible assets mean?
- Cash spent on acquiring non-physical assets like patents or software.
- How do you interpret payments to acquire intangible assets?
- Increased spending often signals strategic investment in R&D or market expansion through external acquisitions.
- How does payments to acquire intangible assets compare across companies?
- Common in technology, pharmaceutical, and media industries where intellectual property is a key value driver.